S. Schmaus

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Ulrich Bogdahn, Peter Hau, Günther Stockhammer et al. · Neuro-Oncology · 2010 · 428 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of TGF- <i>β</i> 2 with AP 12009 in Recurrent Malignant Gliomas: From Preclinical to Phase I/II Studies

Peter Hau, Piotr Jachimczak, Reimar Schlingensiepen et al. · Oligonucleotides · 2007 · 217 citations

Medicine, Oncology, Pharmacology +13

Antisense Therapeutics for Tumor Treatment: The TGF-beta2 Inhibitor AP 12009 in Clinical Development Against Malignant Tumors

Karl‐Hermann Schlingensiepen, Birgit Fischer-Blass, S. Schmaus et al. · Recent results in cancer research/Recent Results in Cancer Research · 2007 · 85 citations

Medicine, Oncology, Pharmacology +10

Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.

Helmut Oettle, Andreas Hilbig, T Seufferlein et al. · Journal of Clinical Oncology · 2011 · 25 citations

Medicine, Oncology, Pharmacology +11

The Reading Frame BPLF1 of Epstein-Barr Virus: A Homologue of Herpes Simplex Virus Protein VP16

S. Schmaus, Hans Wolf, Fritz Schwarzmann · Virus Genes · 2004 · 17 citations

Life Sciences, Microbiology, Molecular Biology +7